Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. A few FDA approvals came through, with Puma Biotechnology Inc (NASDAQ: PBYI ) getting a label expansion for its breast cancer drug Nerlynx and Novartis AG (NYSE: NVS )'s Entresto, a combo therapy, given the go ahead for pediatric heart failure. Here are the key biotech catalysts for the unfolding week. Conferences Related Link: Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement PDUFA Dates The FDA is scheduled to rule on Pfenex Inc (NYSE: PFNX )'s PF708, a therapeutic equivalent of Eli Lilly And Co (NYSE: LLY )'s Forteo, which was approved in 2002 to treat osteoporosis in men and menopausal women, who are at high risk of having a fracture. The PDUFA date is set for Monday.